Please visit answersincme.com/WZP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses foundational elements of this emerging technology and its implications in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential b ..read more

Please visit answersincme.com/XGU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses capabilities and potential applications of generative AI in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential benefits and ri ..read more

Please visit answersincme.com/GXJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses neoadjuvant immunotherapy in resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to select an appropriate treatment approach for patients with resectable CSCC; and Review strategies to enha ..read more

Please visit answersincme.com/AUY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the role of dual immunotherapeutic approaches to the management of advanced melanoma. Upon completion of this activity, participants should be better able to: Review the clinical goals of patients with advanced melanoma receiving immunotherapy-based treatment; Describe the long-term clinical profiles of dual immunotherapeutic approaches to the management of advanced melanoma; and Outline evidence-based, immun ..read more

Please visit answersincme.com/PJR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Jonathan Barker, BSc, MB, BS, MD, FRCP, an expert in dermatology, discusses unmet therapeutic needs in the treatment of generalized pustular psoriasis (GPP). Upon completion of this activity, participants should be better able to: Recognize the burden of generalized pustular psoriasis (GPP), including unmet therapeutic needs; Explain the rationale for the use of IL-36 receptor inhibitors in treating GPP; and Describe the clinical profiles o ..read more

Please visit answersincme.com/ADB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the rationale and clinical data for incorporating neoadjuvant immunotherapy into the treatment of resectable cutaneous squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for incorporating neoadjuvant immunotherapy in the treatment of resectable CSCC; Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC ..read more

Please visit answersincme.com/EXA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Outline guideline-recommended approaches to the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) using PD-1 inhibitors; Review the latest clinical data for first-line PD-1 inhibitor–based t ..read more

Please visit answersincme.com/SRG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the diagnosis and treatment of prurigo nodularis. Upon completion of this activity, participants should be better able to: Recognize the need for treatment intensification in patients with prurigo nodularis (PN), including patients of color, using novel biologic therapies; Review the clinical profiles of novel biologic therapies for PN; and Outline clinical factors that may facilitate the optimal use of biolog ..read more

Please visit answersincme.com/CAC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses the use of neoadjuvant-adjuvant immunotherapy to improve outcomes in patients with resectable melanoma. Upon completion of this activity, participants should be better able to: Review the rationale for the use of neoadjuvant-adjuvant immunotherapy for patients with resectable melanoma; Describe the clinical profiles of the emerging neoadjuvant-adjuvant immunotherapeutic regimens in patients with resectable me ..read more